Ron Do, PhD Email Ron Do
- ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
Dr. Ron Do, Ph.D., is an Assistant Professor in the Department of Genetics and Genomic Sciences. He is appointed as a member of the Charles Bronfman Institute for Personalized Medicine, the Center for Statistical Genetics, the Icahn Institute for Data Science and Genomic Technology, and the Zena and Michael A. Weiner Cardiovascular Institute.
Prior to joining Mount Sinai, Dr. Do was a Postdoctoral Fellow (2010 to 2013) and Instructor in Medicine (2013 to 2015) at the Center for Human Genetic Research at Massachusetts General Hospital and Harvard Medical School, and a research affiliate at the Broad Institute of MIT and Harvard.
Dr. Do is a human geneticist interested in understanding the genetic and biological bases of cardiovascular disease. He has pursued this interest by applying methods from human genetics, genetic epidemiology, statistical genetics, population genetics and computing to large-scale human genotyping and sequencing datasets. His research has focused on assessing the role of rare variants on myocardial infarction, inferring causal effects of risk factors for complex disease, and implementing a population genetics framework to measure differences in the efficiency of natural selection between human populations.
Cardiovascular, Computational Biology, Epigenetics, Genetics, Genomics, Human Genetics and Genetic Disorders, Systems Biology
Multi-Disciplinary Training Area
Genetics and Data Science [GDS]
BSc, University of British Columbia
MSc, University of British Columbia
PhD, McGill University
Post-doc, Massachusetts General Hospital/Broad Institute/Harvard Medical School
Instructor, Harvard Medical School
Canadian Institutes of Health Research
Do Lab Description
The Do Lab's primary research aim is to discover the genetic and biological bases of cardiovascular disease. To this end, the Lab has focused on the following research areas.
1) Implementing computational approaches to analyze exome sequencing data with a view to discovering novel genes that confer risk for plasma lipids and myocardial infarction (MI). We led a study that analyzed exome sequencing data in families with Mendelian lipid disorders. In this project, we discovered compound heterozygote nonsense mutations in the ANGPTL3 gene as a cause of a novel Mendelian lipid disorder called Familial Combined Hypolipidemia (PMID: 20942659). We expanded upon this work to the study of a large-scale rare variant association study using exome sequencing in 10,000 cases and controls for MI.In this study, we identified a burden of rare mutations in the APOA5 and LDLR genes conferring risk for MI (PMID: 25487149). From this work, we have contributed insights and perspectives to the literature on how best to design and conduct rare variant association studies (PMID: 22983955).
2) Developing and implementing statistical approaches to analyze the causal effects of risk factors for complex disease. We have developed and implemented a method to isolate causal influences amongst a set of correlated risk factors for disease. We applied this approach to investigate the causal influence of plasma lipids on coronary artery disease (CAD). We discovered, using a model accounting for effects on low-density lipoprotein cholesterol and/or high-density lipoprotein cholesterol, that the strength of a polymorphism's effect on triglyceride levels is correlated with the magnitude of its effect on CAD risk, providing evidence that triglyceride-rich lipoproteins may be causally related to CAD (PMID: 24097064).
3) Developing and implementing a population genetics framework to measure the efficiency of natural selection in human populations with a view to understanding the genetic architecture of complex disease. We have developed a population genetics framework to assess the effect of a population bottleneck on the deleterious load in ancient and modern human populations. We observed no evidence of a difference in efficiency of natural selection between modern human populations. This work has improved our understanding of the role of specific population genetic forces in human history and their impact on the genetic architecture of complex disease (PMID: 25581429).
A complete list of publications from the Do lab can be found here.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Do during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Pensieve Health
- Variant Bio
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Pensieve Health
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Goldfinch Bio
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.